Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
Authors:
- Daniel Martin KlotzDKDaniel Martin Klotz
- Franziska Maria SchwarzFSFranziska Maria Schwarz
- Anna DubrovskaADAnna Dubrovska
- Kati SchusterKSKati Schuster
- Mirko TheisMTMirko Theis
- Alexander KrügerAKAlexander Krüger
- Oliver KutzOKOliver Kutz
- Theresa LinkTLTheresa Link
- Pauline WimbergerPWPauline Wimberger
- Stephan DrukewitzSDStephan Drukewitz
- Frank BuchholzFrank Buchholz
- Jürgen ThomaleJTJürgen Thomale
Open Access
Abstract
Overcoming PARPi resistance is a high clinical priority. We established and characterized comparative in vitro models of acquired PARPi resistance, derived from either a BRCA1-proficient or BRCA1-deficient isogenic background by long-term exposure to olaparib. While parental cell lines already exhibited a certain level of intrinsic activity of multidrug resistance (MDR) proteins, resulting PARPi-resistant cells from both models further converted toward MDR. In both models, the PARPi-resistant phenotype was shaped by (i) cross-resistance to other PARPis (ii) impaired susceptibility toward the formation of DNA-platinum adducts upon exposure to cisplatin, which could be reverted by the drug efflux inhibitors verapamil or diphenhydramine, and (iii) reduced PARP-trapping activity. However, the signature and activity of ABC-transporter expression and the cross-resistance spectra to other chemotherapeutic drugs considerably diverged between the BRCA1-proficient vs. BRCA1-deficient models. Using dual-fluorescence co-culture experiments, we observed that PARPi-resistant cells had a competitive disadvantage over PARPi-sensitive cells in a drug-free medium. However, they rapidly gained clonal dominance under olaparib selection pressure, which could be mitigated by the MRP1 inhibitor MK-751. Conclusively, we present a well-characterized in vitro model, which could be instrumental in dissecting mechanisms of PARPi resistance from HR-proficient vs. HR-deficient background and in studying clonal dynamics of PARPi-resistant cells in response to experimental drugs, such as novel olaparib-sensitizers.Keywords
This publication has 51 references indexed in Scilit:
- The Subread aligner: fast, accurate and scalable read mapping by seed-and-voteNucleic Acids Research, 2013
- Trapping of PARP1 and PARP2 by Clinical PARP InhibitorsCancer Research, 2012
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25BLaboratory Investigation, 2011
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Chapter 6 DNA Damage Response and Apoptosis2008
- Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing RadiationMolecular Cancer Research, 2007
- 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)Annals of Oncology, 2005